Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

677 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Wen PY, et al. Among authors: wick w. J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15. J Clin Oncol. 2010. PMID: 20231676
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
Combs SE, Kieser M, Rieken S, Habermehl D, Jäkel O, Haberer T, Nikoghosyan A, Haselmann R, Unterberg A, Wick W, Debus J. Combs SE, et al. Among authors: wick w. BMC Cancer. 2010 Sep 6;10:478. doi: 10.1186/1471-2407-10-478. BMC Cancer. 2010. PMID: 20819220 Free PMC article. Clinical Trial.
Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial.
Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jäkel O, Haberer T, Haselmann R, Unterberg A, Wick W, Debus J. Combs SE, et al. Among authors: wick w. BMC Cancer. 2010 Oct 6;10:533. doi: 10.1186/1471-2407-10-533. BMC Cancer. 2010. PMID: 20925951 Free PMC article. Clinical Trial.
Clinical trial end points for high-grade glioma: the evolving landscape.
Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Reardon DA, et al. Among authors: wick w. Neuro Oncol. 2011 Mar;13(3):353-61. doi: 10.1093/neuonc/noq203. Epub 2011 Feb 9. Neuro Oncol. 2011. PMID: 21310734 Free PMC article. Review.
Outcome and prognostic factors of radiation therapy for medulloblastoma.
Rieken S, Mohr A, Habermehl D, Welzel T, Lindel K, Witt O, Kulozik AE, Wick W, Debus J, Combs SE. Rieken S, et al. Among authors: wick w. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e7-e13. doi: 10.1016/j.ijrobp.2010.12.042. Epub 2011 Feb 23. Int J Radiat Oncol Biol Phys. 2011. PMID: 21345611
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.
Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. Galanis E, et al. Among authors: wick w. Lancet Oncol. 2012 May;13(5):e196-204. doi: 10.1016/S1470-2045(11)70406-5. Lancet Oncol. 2012. PMID: 22554547 Review.
677 results